The Europe Cardiac Safety Services Market would witness market growth of 10.6% CAGR during the forecast period (2022-2028).
There are additional factors that contribute to CVDs. These are a consequence of the three main causes urbanization, population aging, and globalization — that are causing social, economic, and cultural transformations. Additionally, pharmacological therapy for diabetes, high blood lipids, and hypertension is required to lower cardiovascular risk and stop strokes and heart attacks in those who have these disorders.
Given the size of the benefit anticipated in a given population and in light of the alternatives available, a product is considered safe if its risks are considered acceptable. The science of cardiac safety can benefit greatly from this definition which encompasses the idea of benefit-risk evaluation, "one of the fundamental components of the science of safety,”.
An agency must determine that an investigational medicine has a positive benefit-risk balance before approving it for sale. When requesting marketing authorization, sponsors have a duty to give regulatory bodies the most accurate and comprehensive safety (and efficacy) data available. The pharmaceutical sector continues to face significant challenges in ensuring the safety of new medical products.
More than 50 million people in Europe have more than one chronic disease, whether due to synergy in the development of the illnesses, similar underlying risk profiles, or just random co-occurrence. The cost of treating and caring for people with multiple illnesses tends to increase significantly with the number and combination of comorbidities, but the tendency varies for some individual diseases. This has made it more difficult to diagnose major illnesses.
The Germany market dominated the Europe Cardiac Safety Services Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $70.6 Million by 2028. The UK market is anticipated to grow at a CAGR of 9.7% during (2022 - 2028). Additionally, The France market would exhibit a CAGR of 11.4% during (2022 - 2028).
Based on Type, the market is segmented into Integrated and Standalone. Based on End User, the market is segmented into Pharmaceutical & Biopharmaceutical Companies and Contract Research Organizations. Based on Type of Service, the market is segmented into ECG/Holter Measurement, Blood Pressure Measurement, Cardiovascular Imaging, Thorough QT Studies, and Others. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
Free Valuable Insights: The Global Cardiac Safety Services Market will Hit $1.1 Billion by 2028, at a CAGR of 11.1%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Koninklijke Philips N.V., Clario, IQVIA Holdings, Inc., Laboratory Corporation of America Holdings, Pharmaceutical Product Development, Inc., SGS S.A., Banook Group, Biotrial Research SAS, Certara, Inc., and Celerion.
By Type
By End User
By Type of Service
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
